Molecular Predictors Of Ritlecitinib Efficacy In Alopecia Areata: Role Of JAK3-Dependent Inflammation And Follicular Integrity

This study investigates molecular predictors of ritlecitinib efficacy in treating alopecia areata (AA), focusing on JAK3-dependent inflammation and follicular integrity. In a post hoc analysis of the ALLEGRO-2a phase 2a trial involving 17 participants, researchers found that lower baseline expression of type I immune genes, such as IL15 and IL2RA, was significantly associated with greater clinical improvement at Week 24. This suggests that reduced inflammatory priming enhances drug responsiveness. Additionally, higher expression of hair follicle-specific structural genes predicted favorable long-term outcomes, indicating preserved regenerative capacity. These findings propose that a composite molecular phenotype of low JAK3-mediated inflammation and intact follicular architecture identifies AA patients most likely to benefit from ritlecitinib, warranting further validation in larger cohorts.